Modulation of Bax and mTOR for cancer therapeutics

A rationale exists for pharmacologic manipulation of the serine (S)184 phosphorylation site of the proapoptotic Bcl2 family member Bax as an anticancer strategy. Here we report the refinement of the Bax agonist SMBA1 to generate CYD-2-11, which has characteristics of a suitable clinical lead compoun...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Li, Rui, Ding, Chunyong, Zhang, Jun, Xie, Maohua, Park, Dongkyoo, Ding, Ye, Chen, Guo, Zhang, Guojing, Gilbert-Ross, Melissa, Zhou, Wei, Marcus, Adam I., Sun, Shi-Yong, Chen, Zhuo G., Sica, Gabriel L., Ramalingam, Suresh S., Magis, Andrew T., Fu, Haian, Khuri, Fadlo R., Curran, Walter J., Owonikoko, Taofeek K., Shin, Dong M., Zhou, Jia, Deng, Xingming
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503158/
https://ncbi.nlm.nih.gov/pubmed/28381544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-2356
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados